Abstract
Background In males, the relationship between pubertal timing and depression is understudied and less consistent than in females, likely for reasons of unmeasured confounding. To clarify this relationship, a combined epidemiological and genetic approach was chosen to exploit the methodological advantages of both approaches.
Methods Data from 2,026 males from a nationwide study (KiGGS) were used to investigate the non-/linear relationship between pubertal timing defined by the age at voice break and major depressive disorder (MDD), considering a multitude of potential confounders and their interactions with pubertal timing. This analysis was complemented by Mendelian Randomization (MR), which is robust to inferential problems inherent to epidemiological studies. We used 71 single nucleotide polymorphisms related to pubertal timing in males as instrumental variable to clarify its causal relationship with MDD based on data from 807,553 individuals (246,363 cases and 561,190 controls) by univariable and multivariable MR, including BMI as pleiotropic phenotype.
Results Univariable MR indicated a causal effect of pubertal timing on MDD risk (inverse-variance weighted: OR=0.93, 95%-CI [0.87–0.99)], p=.03). However, this was not confirmed by multivariable MR (inverse-variance weighted: OR=0.95, 95%-CI [0.88–1.02)], p=.13), consistent with the epidemiological approach (OR=1.01, 95%-CI [0.81–1.26], p=.93). Instead, the multivariable MR study indicated a causal relationship of BMI with MDD by two of three methods.
Conclusions Pubertal timing is not related to MDD risk in males. Considering the adverse health outcomes of higher BMI levels, our findings support the rationale for preventive measures to address obesity and its related risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Charite Berlin (baseline and wave 1) and the ethics committee of the Hannover Medical School (wave 2) gave ethical approval of the KiGGS study. Details on the ethical approval concerning the GWAS used are provided in the respective study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The reported results related to the KiGGS study are based on a secondary analysis of data provided by the Robert Koch Institute (RKI), Germany. Requests to access the datasets should, therefore, be directed to the RKI (kiggsinfo{at}rki.de). Publicly available datasets analyzed in this study can be found here: https://www.ebi.ac.uk/gwas/. Original data generated and analyzed during this study (i.e., harmonized genetic data) are part of the online Supplementary Material.
